Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure

Data from 2 large randomized clinical trials

Serge Masson, Inder Anand, Chiara Favero, Simona Barlera, Tarcisio Vago, Federico Bertocchi, Aldo P. Maggioni, Luigi Tavazzi, Gianni Tognoni, Jay N. Cohn, Roberto Latini

Research output: Contribution to journalArticle

158 Citations (Scopus)

Abstract

Background - Cardiac troponins are emerging as important prognostic markers in chronic cardiovascular conditions like stable coronary artery disease or chronic heart failure (HF). Less is known about the relation between serial measurements of high-sensitivity cardiac troponin T (hs-cTnT) and future events in HF. We determined the association between changes over time in hs-cTnT and outcome in patients with chronic HF. Methods and Results - We analyzed 5284 patients with chronic HF from 2 independent randomized clinical trials, the Valsartan Heart Failure Trial (Val-HeFT) (n=4053) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) trial (n=1231). hs-cTnT was measured at randomization and after 3 months (GISSI-HF) or 4 months of follow-up (Val-HeFT). The association between changes over time of hs-cTnT and various outcomes was tested in multivariable models. In both studies, increases in hs-cTnT levels over time were associated with age, diabetes mellitus, worsening of renal function (reduction in estimated glomerular filtration rate), and baseline and increases in N-terminal pro-brain natriuretic peptide concentrations. Increases in hs-cTnT concentrations were associated with all-cause mortality (incidence rates, 8.19 [7.51-8.88] and 6.79 [5.98-7.61] per 100 person-years in Val-HeFT and GISSI-HF, respectively, with hazard ratios [95% confidence intervals] of 1.59 [1.39-1.82] and 1.88 [1.50-2.35]) after adjustment for conventional risk factors and baseline levels of hs-cTnT and N-terminal pro-brain natriuretic peptide. Changes in hs-cTnT concentration modestly improved prognostic discrimination beyond baseline values for fatal outcomes only. Conclusions - Despite very low circulating concentrations, changes in hs-cTnT concentrations over time are robust predictors of future cardiovascular events in patients with chronic HF but add limited prognostic discrimination.

Original languageEnglish (US)
Pages (from-to)280-288
Number of pages9
JournalCirculation
Volume125
Issue number2
DOIs
StatePublished - Jan 17 2012

Fingerprint

Troponin T
Randomized Controlled Trials
Heart Failure
Valsartan
Brain Natriuretic Peptide
Troponin
Fatal Outcome
Random Allocation
Glomerular Filtration Rate
Coronary Artery Disease
Diabetes Mellitus

Keywords

  • biomarkers
  • heart failure
  • natriuretic peptides
  • prognosis
  • troponin T

Cite this

Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure : Data from 2 large randomized clinical trials. / Masson, Serge; Anand, Inder; Favero, Chiara; Barlera, Simona; Vago, Tarcisio; Bertocchi, Federico; Maggioni, Aldo P.; Tavazzi, Luigi; Tognoni, Gianni; Cohn, Jay N.; Latini, Roberto.

In: Circulation, Vol. 125, No. 2, 17.01.2012, p. 280-288.

Research output: Contribution to journalArticle

Masson, S, Anand, I, Favero, C, Barlera, S, Vago, T, Bertocchi, F, Maggioni, AP, Tavazzi, L, Tognoni, G, Cohn, JN & Latini, R 2012, 'Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: Data from 2 large randomized clinical trials', Circulation, vol. 125, no. 2, pp. 280-288. https://doi.org/10.1161/CIRCULATIONAHA.111.044149
Masson, Serge ; Anand, Inder ; Favero, Chiara ; Barlera, Simona ; Vago, Tarcisio ; Bertocchi, Federico ; Maggioni, Aldo P. ; Tavazzi, Luigi ; Tognoni, Gianni ; Cohn, Jay N. ; Latini, Roberto. / Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure : Data from 2 large randomized clinical trials. In: Circulation. 2012 ; Vol. 125, No. 2. pp. 280-288.
@article{803c19a127f24e2aba7573ba49f128b9,
title = "Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: Data from 2 large randomized clinical trials",
abstract = "Background - Cardiac troponins are emerging as important prognostic markers in chronic cardiovascular conditions like stable coronary artery disease or chronic heart failure (HF). Less is known about the relation between serial measurements of high-sensitivity cardiac troponin T (hs-cTnT) and future events in HF. We determined the association between changes over time in hs-cTnT and outcome in patients with chronic HF. Methods and Results - We analyzed 5284 patients with chronic HF from 2 independent randomized clinical trials, the Valsartan Heart Failure Trial (Val-HeFT) (n=4053) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) trial (n=1231). hs-cTnT was measured at randomization and after 3 months (GISSI-HF) or 4 months of follow-up (Val-HeFT). The association between changes over time of hs-cTnT and various outcomes was tested in multivariable models. In both studies, increases in hs-cTnT levels over time were associated with age, diabetes mellitus, worsening of renal function (reduction in estimated glomerular filtration rate), and baseline and increases in N-terminal pro-brain natriuretic peptide concentrations. Increases in hs-cTnT concentrations were associated with all-cause mortality (incidence rates, 8.19 [7.51-8.88] and 6.79 [5.98-7.61] per 100 person-years in Val-HeFT and GISSI-HF, respectively, with hazard ratios [95{\%} confidence intervals] of 1.59 [1.39-1.82] and 1.88 [1.50-2.35]) after adjustment for conventional risk factors and baseline levels of hs-cTnT and N-terminal pro-brain natriuretic peptide. Changes in hs-cTnT concentration modestly improved prognostic discrimination beyond baseline values for fatal outcomes only. Conclusions - Despite very low circulating concentrations, changes in hs-cTnT concentrations over time are robust predictors of future cardiovascular events in patients with chronic HF but add limited prognostic discrimination.",
keywords = "biomarkers, heart failure, natriuretic peptides, prognosis, troponin T",
author = "Serge Masson and Inder Anand and Chiara Favero and Simona Barlera and Tarcisio Vago and Federico Bertocchi and Maggioni, {Aldo P.} and Luigi Tavazzi and Gianni Tognoni and Cohn, {Jay N.} and Roberto Latini",
year = "2012",
month = "1",
day = "17",
doi = "10.1161/CIRCULATIONAHA.111.044149",
language = "English (US)",
volume = "125",
pages = "280--288",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure

T2 - Data from 2 large randomized clinical trials

AU - Masson, Serge

AU - Anand, Inder

AU - Favero, Chiara

AU - Barlera, Simona

AU - Vago, Tarcisio

AU - Bertocchi, Federico

AU - Maggioni, Aldo P.

AU - Tavazzi, Luigi

AU - Tognoni, Gianni

AU - Cohn, Jay N.

AU - Latini, Roberto

PY - 2012/1/17

Y1 - 2012/1/17

N2 - Background - Cardiac troponins are emerging as important prognostic markers in chronic cardiovascular conditions like stable coronary artery disease or chronic heart failure (HF). Less is known about the relation between serial measurements of high-sensitivity cardiac troponin T (hs-cTnT) and future events in HF. We determined the association between changes over time in hs-cTnT and outcome in patients with chronic HF. Methods and Results - We analyzed 5284 patients with chronic HF from 2 independent randomized clinical trials, the Valsartan Heart Failure Trial (Val-HeFT) (n=4053) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) trial (n=1231). hs-cTnT was measured at randomization and after 3 months (GISSI-HF) or 4 months of follow-up (Val-HeFT). The association between changes over time of hs-cTnT and various outcomes was tested in multivariable models. In both studies, increases in hs-cTnT levels over time were associated with age, diabetes mellitus, worsening of renal function (reduction in estimated glomerular filtration rate), and baseline and increases in N-terminal pro-brain natriuretic peptide concentrations. Increases in hs-cTnT concentrations were associated with all-cause mortality (incidence rates, 8.19 [7.51-8.88] and 6.79 [5.98-7.61] per 100 person-years in Val-HeFT and GISSI-HF, respectively, with hazard ratios [95% confidence intervals] of 1.59 [1.39-1.82] and 1.88 [1.50-2.35]) after adjustment for conventional risk factors and baseline levels of hs-cTnT and N-terminal pro-brain natriuretic peptide. Changes in hs-cTnT concentration modestly improved prognostic discrimination beyond baseline values for fatal outcomes only. Conclusions - Despite very low circulating concentrations, changes in hs-cTnT concentrations over time are robust predictors of future cardiovascular events in patients with chronic HF but add limited prognostic discrimination.

AB - Background - Cardiac troponins are emerging as important prognostic markers in chronic cardiovascular conditions like stable coronary artery disease or chronic heart failure (HF). Less is known about the relation between serial measurements of high-sensitivity cardiac troponin T (hs-cTnT) and future events in HF. We determined the association between changes over time in hs-cTnT and outcome in patients with chronic HF. Methods and Results - We analyzed 5284 patients with chronic HF from 2 independent randomized clinical trials, the Valsartan Heart Failure Trial (Val-HeFT) (n=4053) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) trial (n=1231). hs-cTnT was measured at randomization and after 3 months (GISSI-HF) or 4 months of follow-up (Val-HeFT). The association between changes over time of hs-cTnT and various outcomes was tested in multivariable models. In both studies, increases in hs-cTnT levels over time were associated with age, diabetes mellitus, worsening of renal function (reduction in estimated glomerular filtration rate), and baseline and increases in N-terminal pro-brain natriuretic peptide concentrations. Increases in hs-cTnT concentrations were associated with all-cause mortality (incidence rates, 8.19 [7.51-8.88] and 6.79 [5.98-7.61] per 100 person-years in Val-HeFT and GISSI-HF, respectively, with hazard ratios [95% confidence intervals] of 1.59 [1.39-1.82] and 1.88 [1.50-2.35]) after adjustment for conventional risk factors and baseline levels of hs-cTnT and N-terminal pro-brain natriuretic peptide. Changes in hs-cTnT concentration modestly improved prognostic discrimination beyond baseline values for fatal outcomes only. Conclusions - Despite very low circulating concentrations, changes in hs-cTnT concentrations over time are robust predictors of future cardiovascular events in patients with chronic HF but add limited prognostic discrimination.

KW - biomarkers

KW - heart failure

KW - natriuretic peptides

KW - prognosis

KW - troponin T

UR - http://www.scopus.com/inward/record.url?scp=84856106687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856106687&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.111.044149

DO - 10.1161/CIRCULATIONAHA.111.044149

M3 - Article

VL - 125

SP - 280

EP - 288

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 2

ER -